Separation of dendritic cells from highly purified human monocytes by counterflow centrifugation induces tissue factor expression.
BACKGROUND
In vitro generation of dendritic cells (DCs) from human monocytes represents a promising tool in immunotherapy. However, it is not known whether the separation of DCs from monocytes induces tissue factor expression and therefore may trigger coagulation in patients receiving these DC preparations. The aim of this study is thus to analyze tissue factor expression on monocyte-derived DCs and to compare their ability to trigger thrombin generation to that of macrophages obtained from the same monocytes.


METHODS
Human monocytes are separated by leukapheresis and washed by using counterflow centrifugation in sterile, endotoxin-free conditions. Macrophages are grown from human monocytes in the presence of GM-CSF alone and immature DCs are grown in the presence of GM-CSF plus IL-4 for 5 days with fetal calf serum (IDC-FCS). Immature DCs are also grown from human monocytes for 7 days in the presence of GM-CSF plus IL-4 with human group AB serum (IDC-HS). The addition of prostaglandin E(2) and TNFalpha in this culture medium at Day 5 leads to mature DCs (MDC-HS). Tissue factor mRNA expression is studied by RT-PCR analysis. Tissue factor antigen is measured by ELISA in cell lysates and by direct flow cytometry. The procoagulant activity of intact cells is assessed by using an amidolytic assay or a chronometric assay.


RESULTS
IDC-FCS express tissue factor mRNA and antigen and trigger thrombin generation. Procoagulant activity of IDC-FCS is dependent on both tissue factor expression and exposure to anionic phospholipid. Monocyte-derived macrophages cultured for 5 days with GM-CSF alone express lower levels of tissue factor mRNA, tissue factor antigen, and procoagulant activity than IDC-FCS. IDC-HS and MDC-HS also express high levels of tissue factor mRNA and antigen and support procoagulant activity.


CONCLUSIONS
Monocyte-derived DCs express a high level of functional tissue factor and support procoagulant activity. This finding should be taken into account in clinical trials.
Broussas
M
M
Central Hematology Laboratory, University of Reims Medical Center, Reims, France.
Cornillet-Lefebvre
P
P
Bernard
J
J
Adjizian
J C
JC
Potron
G
G
Nguyên
P
P
D000818:Animals; D000838:Anions; D000941:Antigens; D002417:Cattle; D002469:Cell Separation / Q000379:methods*; D002478:Cells, Cultured; D002498:Centrifugation / Q000379:methods; D003029:Coagulants / Q000378:metabolism; D003713:Dendritic Cells / Q000166:cytology*; D005312:Fetal Blood / Q000166:cytology; D006801:Humans; D009000:Monocytes / Q000166:cytology*; D010743:Phospholipids / Q000096:biosynthesis; D012333:RNA, Messenger / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013925:Thromboplastin / Q000235:genetics* / Q000276:immunology
D000838:Anions; D000941:Antigens; D003029:Coagulants; D010743:Phospholipids; D012333:RNA, Messenger; D013925:Thromboplastin